Filing Flows › 10x Genomics (TXG) › Q3 2026 › vs Q2 2026
10x Genomics (TXG) Q3 2026 vs Q2 2026 (quarter over quarter)
10x Genomics's revenue fell $369K (-0.2%) from $151M in Q2 2026 to $151M in Q3 2026. The biggest changes: Consumables +$3.6M (+3%); Services −$1.7M (-16%); Instruments −$803K (-10%).
10x Genomics, Q3 2026: revenue $151M (+1% year over year), operating margin -10.7%, net loss $19.4M, operating cash flow $15.8M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 9.9% | 10.2% | -0.3 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Single Cell | $93.1M | $88.5M | $4.7M | +5% |
| Spatial | $41.2M | $42.3M | −$1.1M | -3% |
| Single Cell | $3.8M | $3.1M | $695K | +23% |
| Spatial | $3.1M | $4.6M | −$1.5M | -33% |
| Consumables | $134M | $131M | $3.6M | +3% |
| Instruments | $6.9M | $7.7M | −$803K | -10% |
| Services | $9.0M | $10.7M | −$1.7M | -16% |
| Revenue | $151M | $151M | −$369K | -0.2% |
| Net loss | $19.4M | $17.9M | $1.5M | +8% |
| Costs & expenses | $170M | $171M | −$499K | -0.3% |
| Operating costs | $167M | $171M | −$3.9M | -2% |
| Interest & other, net | $2.4M | −$910K | $3.3M | — |
| Income tax | $949K | −$714K | $1.7M | — |
| Cost of revenue | $37.7M | $38.5M | −$799K | -2% |
| Operating cash sources | $35.3M | $34.9M | $353K | +1% |
| Depreciation & amortization | $9.5M | $9.7M | −$160K | -2% |
| Share-based compensation | $23.1M | $25.6M | −$2.5M | -10% |
| Working capital & other | $2.7M | −$375K | $3.0M | — |
| Net loss absorbed | $19.4M | $17.9M | $1.5M | +8% |
| Operating cash flow | $15.8M | $17.0M | −$1.1M | -7% |
| Free cash flow (OCF − capex) | $14.9M | $15.4M | −$524K | -3% |
| Capital expenditures | $971K | $1.6M | −$617K | -39% |
Questions
How much did 10x Genomics's revenue grow quarter over quarter in Q3 2026?
10x Genomics's revenue fell $369K (-0.2%) from $151M in Q2 2026 to $151M in Q3 2026.
What drove 10x Genomics's revenue change in Q3 2026?
Consumables +$3.6M (+3%); Services −$1.7M (-16%); Instruments −$803K (-10%).